Company Description
Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders.
The company’s product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase II clinical trial to treat major depressive disorder.
It also develops PH80, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase II clinical trial for the treatment of vasomotor symptoms, including hot flashes due to menopause, premenstrual dysphoric disorder, and other women’s health disorders; PH15, an investigational pherine nasal spray, which is in Phase II clinical trial for the treatment to improve cognitive impairment caused by mental fatigue and potentially other disorders; PH284, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase II clinical trial to treat loss of appetite associated with chronic disorders, such as cancer or heart disease, as well as cachexia; and AV-101, an oral prodrug that targets N-methyl-D-aspartate receptor in the brain for treating depression and neurological disorders.
In addition, the company’s clinical-stage pipeline consists of intranasal product candidates comprising pherines.
It has a license and collaboration agreement with AffaMed Therapeutics, Inc. to develop, manufacture, and commercialize fasedienol for multiple anxiety-related disorders.
Vistagen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 1998 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 57 |
| CEO | Shawn Singh |
Contact Details
Address: 343 Allerton Avenue South San Francisco, California 94080 United States | |
| Phone | 650 577 3600 |
| Website | vistagen.com |
Stock Details
| Ticker Symbol | VTGN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001411685 |
| CUSIP Number | 92840H202 |
| ISIN Number | US92840H4002 |
| Employer ID | 20-5093315 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Shawn K. Singh J.D. | President, Chief Executive Officer and Director |
| Joshua S. Prince M.B.A. | Chief Operating Officer |
| Reid G. Adler Esq., J.D. | Chief Legal Officer |
| Mark Adrian McPartland | Senior Vice President of Investor Relations |
| Michelle Peters Wellington | Vice President of Communications |
| Elissa Cote | Chief Corporate Development Officer |
| Trisha Fitzmaurice | Senior Vice President of Human Resources |
| Dr. Allen Easley Cato III, M.D., Ph.D. | Senior Vice President of Development Operations |
| Dr. Mark J. Ginski Ph.D. | Senior Vice President and Head of Chemistry, Manufacturing and Controls |
| Mark Flather | Senior Vice President of Corporate Strategy and Capital Markets |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 7, 2025 | 10-Q | Quarterly Report |
| Aug 7, 2025 | 8-K | Current Report |
| Jul 28, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jul 28, 2025 | DEF 14A | Other definitive proxy statements |
| Jun 25, 2025 | 8-K | Current Report |
| Jun 17, 2025 | 8-K | Current Report |
| Jun 17, 2025 | 424B5 | Filing |
| Jun 17, 2025 | 10-K | Annual Report |
| Jun 2, 2025 | 8-K | Current Report |
| May 15, 2025 | SCHEDULE 13G/A | Filing |